Capabilities
From sequence to a documented, transferable process
SysGene connects expression, upstream development, recovery, purification, analytical characterization, scale-up and technology transfer around defined program goals.
One connected development plan
Feasibility & Expression Strategy
Assess molecule fit, define the target quality profile and select the platform route.
We assess molecular structure, biological function and post-translational processing requirements to evaluate production feasibility and define the target quality profile. Selection of microbial (E. coli/Pichia) or mammalian (CHO/HEK) expression systems considers protein folding, secretion, purification requirements and the intended manufacturing scale.
Manufacture
Analytical and method development, with 5 L mammalian and 30–1,000 L microbial capacity; 5,000 L planned.
We connect non-GMP microbial and mammalian development with GMP microbial manufacture at 30, 100 and 1,000 L. Fermentation and downstream purification are supported by molecule-specific testing for identity, purity, biological activity and process-related impurities, alongside defined product specifications, operating procedures and batch documentation.
End-to-end microbial
Every stage of a microbial programme, connected
Strain and construct work, fermentation, recovery, purification, analytics, scale-up and transfer are planned as one sequence rather than handed between disconnected teams. Programs may be scoped for GMP or non-GMP manufacture, and specialized capabilities may be delivered through qualified partners.
Discuss a Development NeedDevelopment capabilities
Go deeper on any stage
Upstream development
Expression strategy, host or cell-line work, media and process-mode development.
Explore upstream development→Downstream purification
Primary recovery, capture chromatography and polishing.
Explore downstream purification→Analytics & characterization
Identity, purity, binding, activity and impurity-control methods.
Explore analytics & characterization→Scale-up & transfer
Non-GMP and GMP manufacturing scale, documentation and site-transfer support.
Explore scale-up & transfer→Characterization
Characterization capabilities for peptides, proteins and mAbs
SysGene characterizes molecules across primary, secondary and higher-order structure and biological function, with each analytical programme tailored to the molecule class.
Fewer than 40 amino acids
Peptides

MW ~0.5–5 kDa
- Short linear or simple cyclic chains.
- Lack tertiary folding; highly flexible in solution.
Analytical focus: Molecular weight and LC-MS purity.
More than 40 amino acids
Proteins

MW ~10–100+ kDa
- Complex folded 3D structures (α-helices, β-sheets).
- Susceptible to denaturation and aggregation.
Analytical focus: Secondary and tertiary folding, and activity.
Heterotetramer
Monoclonal antibodies

MW ~150 kDa
- Y-shaped four-chain glycoprotein (two heavy, two light).
- Complex post-translational modifications (PTMs).
Analytical focus: Glycosylation, charge variants and binding.
The US FDA defines a protein as any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size; a polymer of 40 amino acids or fewer is a peptide.
Primary structure
Mass, sequence, disulfide bonds, PTMs, identity and purity.
LC-MS/MS · MALDI-TOF · peptide mapping · Edman · AAA · RP-HPLC
Secondary structure
Fold composition, structural fingerprint and thermal stability.
CD · FTIR · Raman · DSC
Higher-order structure
Tertiary fold, aggregation, fragmentation and oligomeric state.
Fluorescence · SEC-MALS · SEC-HPLC · DLS
Biological characterization
Binding affinity and kinetics, potency and Fc-mediated function.
SPR · cell-based bioassays · ADCC / CDC
Manufacturing capability
Capacity in Hyderabad
SysGene operates in-house mammalian bioreactor capacity at 5 L scale and microbial fermenters from development scale to 30 L, 100 L, and 1,000 L in Hyderabad, with 5,000 L capacity planned. Programs may be scoped for GMP or non-GMP manufacture, subject to facility, product and regulatory fit. Additional capacity and specialized capabilities may be delivered through qualified partners.


Discuss a development need
Tell us where you are in the process and we will map the relevant capabilities to your program.
Contact SysGene

